secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001193125-24-194907
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M
-----------------------------------------------------------

- Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).
- Net loss $10.4M vs $4.4M in Q2 2023; operating loss $8.5M vs $9.1M.
- Adjusted EBITDA $2.9M vs $1.5M; cash and securities $277.2M.
- FY2024 revenue guidance narrowed to $203-210M (5-9% growth); expects positive cash flow from ops.
- Repurchased $2.7M of stock; total installed base 2,656 instruments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524194907/0001193125-24-194907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524194907/d859161d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-194907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer